Your GLP-1 and GIP receptors are already adapted to agonist stimulation, which means the GI adjustment to retatrutide may be less severe than starting from scratch
Because you are functionally considered to be hypothyroid once your thyroid is removed
Some individuals reach their target health milestones on moderate doses

Standard diabetes indication requirements: Documented type 2 diabetes diagnosis (ICD-10 code E11.x) HbA1c measurement within the past 90 days showing 8.0% (some states accept 7.5%) Trial and documented failure of metformin for at least 90 days at maximally tolerated dose Trial and documented failure of at least one additional oral antidiabetic agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days BMI documentation (most states require 27 kg/m) Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2) Standard weight-loss indication requirements (states offering coverage): BMI 30 kg/m, or 27 kg/m with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) Documented failure of behavioral weight-loss program for at least 6 months Documented failure of at least one other weight-loss medication (phentermine, orlistat, or naltrexone/bupropion) for 90 days Letter of medical necessity from prescribing provider Commitment to ongoing nutritional counseling (some plans require documentation of scheduled appointments) The "documented failure" language is where most prior authorizations fail

Copper peptide delivery to follicular tissue may support lysyl oxidase activity and thereby maintain the structural framework within which follicles operate